What are the major opportunities in the GM1 Gangliosidosis market? What are the strategies for the GM1 Gangliosidosis market?

For detailed insights on the major opportunities and strategies in the GM1 Gangliosidosis market, Read More

How does the GM1 Gangliosidosis market relate to the overall economy and other similar markets?

For detailed insights on the key dynamics influencing the GM1 Gangliosidosis market growth and SWOT analysis of the GM1 Gangliosidosis industry, Read More

For detailed insights on the mergers and acquisitions in the GM1 Gangliosidosis industry,

What are the key dynamics influencing the GM1 Gangliosidosis market growth? SWOT analysis of the GM1 Gangliosidosis market. Read More

Global GM1 Gangliosidosis Market Report 2025

Item added to cart!

Report Price : $4490.00

Pages : 175

Format : PDF

Published : December 2025

Delivery Time : 2-3 Business Days

Purchase This Report Download Sample PDF

Purchase This Report

GM1 Gangliosidosis Global Market Report 2025

Name: GM1 Gangliosidosis Global Market Report 2025
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Disease Type (Type 1 GM1 Gangliosidosis, Type 2 GMT Gangliosidosis, Type 3 GMT Gangliosidosis), By Treatment (Anticonvulsants, Bone Marrow Transplantation, Cord-Blood Hematopoietic Stem-Cell Transplantation, Enzyme Replacement, Gene Therapy), By End-User (Research Institutes, Hospitals, Other End-Users) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

GM1 Gangliosidosis Market Overview

• GM1 Gangliosidosis market size has reached to $0.51 billion in 2024

• Expected to grow to $0.87 billion in 2029 at a compound annual growth rate (CAGR) of 11%

• Growth Driver: Rising Adoption Of Gene Therapy Fuels Growth In Rare Disease Treatments

• Market Trend: Strategic Partnership To Advance Gene Therapies For Rare Diseases

• North America was the largest region in 2024.

What Is Covered Under GM1 Gangliosidosis Market?

GM1 gangliosidosis is a rare, inherited neurodegenerative disorder caused by a deficiency of the ß-galactosidase (GLB1) enzyme, leading to toxic accumulation of GM1 gangliosides in the brain and other tissues. It results in progressive neurological decline, developmental delays, muscle weakness, and organ enlargement.

The main disease types in GM1 gangliosidosis are type 1 GM1 gangliosidosis, type 2 GMT gangliosidosis, and type 3 GMT gangliosidosis. Type 1 GM1 gangliosidosis is the most severe form, diagnosed in infancy, characterized by rapid neurological degeneration. Affected children experience progressive motor and cognitive decline, resulting in early death. Treatment options include anticonvulsants, bone marrow transplantation, cord-blood hematopoietic stem cell transplantation, enzyme replacement therapy, and gene therapy. These are utilized in research institutes, hospitals, and others.

GM1 Gangliosidosis Market Size and growth rate 2025 to 2029: Graph

What Is The GM1 Gangliosidosis Market Size 2025 And Growth Rate?

The GM1 gangliosidosis market size has grown rapidly in recent years. It will grow from $0.51 billion in 2024 to $0.57 billion in 2025 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to increase in number of patients suffering from gm1 gangliosidosis, growing area of focus in the gm1 gangliosidosis space, rising prevalence of rare disease awareness, rising popularity of patient-centric research, and increasing focus on early intervention.

What Is The GM1 Gangliosidosis Market Growth Forecast?

The GM1 gangliosidosis market size is expected to see rapid growth in the next few years. It will grow to $0.87 billion in 2029 at a compound annual growth rate (CAGR) of 11.0%. The growth in the forecast period can be attributed to increasing gm1 gangliosidosis cases, rising lysosomal storage disorder, rising number of clinical trials, increasing focus on gene therapy and editing, increasing personalized and precision medicine, and rising adoption of genetic screening programs. Major trends in the forecast period include advancements in gene-editing technologies, integration of technology in healthcare, advancement in diagnostic techniques, advanced formulations, and advancements in genetic therapies.

The forecast of 11.0% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. treatment of this rare pediatric disorder by inflating prices of enzyme replacement therapies developed in the UK and France, resulting in delayed neurological interventions and increasing rare disease treatment costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Book your 30 minutes free consultation with our research experts

What’s The Trade War Impact On Healthcare Services Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

How Is The GM1 Gangliosidosis Market Segmented?

1) By Disease Type: Type 1 GM1 Gangliosidosis, Type 2 GMT Gangliosidosis, Type 3 GMT Gangliosidosis

2) By Treatment: Anticonvulsants, Bone Marrow Transplantation, Cord-Blood Hematopoietic Stem-Cell Transplantation, Enzyme Replacement, Gene Therapy

3) By End-User: Research Institutes, Hospitals, Other End-Users

Subsegments:

1) By Type 1 GM1 Gangliosidosis: Classic Infantile Onset, Atypical Infantile Onset

2) By Type 2 GM1 Gangliosidosis: Classic Juvenile Onset, Atypical Juvenile Onset

3) By Type 3 GM1 Gangliosidosis: Classic Adult Onset, Atypical Adult Onset

What Is Driving The GM1 Gangliosidosis Market? Rising Adoption Of Gene Therapy Fuels Growth In Rare Disease Treatments

The increasing adoption of gene therapy is expected to fuel the growth of the GM1 gangliosidosis market going forward. Gene therapy is a medical treatment that involves altering or replacing genes within a person's cells to treat or prevent disease. The increasing adoption of gene therapy is driven by advancements in genetic research, improved treatment outcomes for previously untreatable conditions, and growing regulatory support for innovative therapies. Gene therapy for GM1 gangliosidosis involves delivering a functional copy of the defective gene (GLB1) to patient cells to restore ß-galactosidase enzyme activity and reduce toxic substrate buildup. For instance, in April 2024, according to the American Society of Gene & Cell Therapy, a US-based non-profit medical and scientific organization, in the fourth quarter, the number of phase III gene therapy clinical trials rose by 10%, marking the first quarterly increase since the third quarter of 2022. Therefore, the increasing adoption of gene therapy is driving the growth of the GM1 gangliosidosis industry.

Who Are The Major Players In The Global GM1 Gangliosidosis Market?

Major companies operating in the GM1 gangliosidosis market are Pfizer Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Sarepta Therapeutics Inc., CRISPR Therapeutics AG, REGENXBIO Inc., Passage Bio Inc., Orchard Therapeutics plc, AVROBIO Inc., uniQure N.V., GEMMA Biotherapeutics Inc., Lysogene S.A., AZAFAROS B.V., BioStrategies LC, Sio Gene Therapies Inc., Gain Therapeutics Inc., Dorphan S.A., bluebird bio Inc., Axovant Gene Therapies Ltd., SphinCS GmbH.

What Are The Key Trends Of The Global GM1 Gangliosidosis Market? Strategic Partnership To Advance Gene Therapies For Rare Diseases

Major companies operating in the GM1 gangliosidosis market are focusing on strategic partnerships to sustain their position in the market. Strategic partnerships play a crucial role in advancing gene therapy development by combining expertise, resources, and technologies to accelerate research, clinical trials, and commercialization. For instance, in October 2024, GEMMA Biotherapeutics Inc., a US-based biotechnology company, partnered with Oswaldo Cruz Foundation (Fiocruz), a Brazil-based health research institution, to develop gene therapies for rare diseases, including GM1 gangliosidosis. The agreement involves up to $100 million in funding from Fiocruz for clinical research and manufacturing, aimed at making these advanced therapies accessible through Brazil's public healthcare system. This collaboration emphasizes technology transfer and aims to democratize access to treatments that were previously limited to higher-income populations.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The GM1 Gangliosidosis Market? Passage Bio Partners With GEMMA Biotherapeutics To Advance Pediatric Gene Therapies

In August 2024, Passage Bio Inc., a US-based biotech company, partnered with GEMMA Biotherapeutics, to advance pediatric gene therapies. As part of this collaboration, Passage Bio is out-licensing three pediatric gene therapies targeting lysosomal storage diseases including PBGM01 for GM1 gangliosidosis, PBKR03 for Krabbe disease, and PBML04 for metachromatic leukodystrophy. GEMMA Biotherapeutics Inc. is a US-based biotechnology research company that specializes in developing and commercializing genetic medicines for rare pediatric diseases.

What Is The Regional Outlook For The Global GM1 Gangliosidosis Market?

North America was the largest region in the GM1 gangliosidosis market in 2024. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the GM1 Gangliosidosis Market?

The GM1 gangliosidosis market consists of revenues earned by entities by providing services such as gene therapy, diagnostic testing, patient care, and clinical trials. The market value includes the value of related goods sold by the service provider or included within the service offering. The GM1 gangliosidosis market also includes sales of diagnostic tools, research kits, biomarkers, and assistive devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the GM1 Gangliosidosis Industry?

The gm1 gangliosidosis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the gm1 gangliosidosis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

GM1 Gangliosidosis Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$0.57 billion
Revenue Forecast In 2034	$0.87 billion
Growth Rate	CAGR of 11% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	The GM1 gangliosidosis market covered in this report is segmented – 1) By Disease Type: Type 1 GM1 Gangliosidosis, Type 2 GMT Gangliosidosis, Type 3 GMT Gangliosidosis 2) By Treatment: Anticonvulsants, Bone Marrow Transplantation, Cord-Blood Hematopoietic Stem-Cell Transplantation, Enzyme Replacement, Gene Therapy 3) By End-User: Research Institutes, Hospitals, Other End-Users Subsegments: 1) By Type 1 GM1 Gangliosidosis: Classic Infantile Onset, Atypical Infantile Onset 2) By Type 2 GM1 Gangliosidosis: Classic Juvenile Onset, Atypical Juvenile Onset 3) By Type 3 GM1 Gangliosidosis: Classic Adult Onset, Atypical Adult Onset
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Pfizer Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Sarepta Therapeutics Inc., CRISPR Therapeutics AG, REGENXBIO Inc., Passage Bio Inc., Orchard Therapeutics plc, AVROBIO Inc., uniQure N.V., GEMMA Biotherapeutics Inc., Lysogene S.A., AZAFAROS B.V., BioStrategies LC, Sio Gene Therapies Inc., Gain Therapeutics Inc., Dorphan S.A., bluebird bio Inc., Axovant Gene Therapies Ltd., SphinCS GmbH.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. GM1 Gangliosidosis Market Characteristics

3. GM1 Gangliosidosis Market Trends And Strategies

4. GM1 Gangliosidosis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global GM1 Gangliosidosis Growth Analysis And Strategic Analysis Framework

5.1. Global GM1 Gangliosidosis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global GM1 Gangliosidosis Market Growth Rate Analysis

5.4. Global GM1 Gangliosidosis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global GM1 Gangliosidosis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global GM1 Gangliosidosis Total Addressable Market (TAM)

6. GM1 Gangliosidosis Market Segmentation

6.1. Global GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Type 1 GM1 Gangliosidosis

Type 2 GMT Gangliosidosis

Type 3 GMT Gangliosidosis

6.2. Global GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Anticonvulsants

Bone Marrow Transplantation

Cord-Blood Hematopoietic Stem-Cell Transplantation

Enzyme Replacement

Gene Therapy

6.3. Global GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Research Institutes

Hospitals

Other End-Users

6.4. Global GM1 Gangliosidosis Market, Sub-Segmentation Of Type 1 GM1 Gangliosidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Classic Infantile Onset

Atypical Infantile Onset

6.5. Global GM1 Gangliosidosis Market, Sub-Segmentation Of Type 2 GM1 Gangliosidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Classic Juvenile Onset

Atypical Juvenile Onset

6.6. Global GM1 Gangliosidosis Market, Sub-Segmentation Of Type 3 GM1 Gangliosidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Classic Adult Onset

Atypical Adult Onset

7. GM1 Gangliosidosis Market Regional And Country Analysis

7.1. Global GM1 Gangliosidosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global GM1 Gangliosidosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific GM1 Gangliosidosis Market

8.1. Asia-Pacific GM1 Gangliosidosis Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China GM1 Gangliosidosis Market

9.1. China GM1 Gangliosidosis Market Overview

9.2. China GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India GM1 Gangliosidosis Market

10.1. India GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan GM1 Gangliosidosis Market

11.1. Japan GM1 Gangliosidosis Market Overview

11.2. Japan GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia GM1 Gangliosidosis Market

12.1. Australia GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia GM1 Gangliosidosis Market

13.1. Indonesia GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea GM1 Gangliosidosis Market

14.1. South Korea GM1 Gangliosidosis Market Overview

14.2. South Korea GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe GM1 Gangliosidosis Market

15.1. Western Europe GM1 Gangliosidosis Market Overview

15.2. Western Europe GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK GM1 Gangliosidosis Market

16.1. UK GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany GM1 Gangliosidosis Market

17.1. Germany GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France GM1 Gangliosidosis Market

18.1. France GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy GM1 Gangliosidosis Market

19.1. Italy GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain GM1 Gangliosidosis Market

20.1. Spain GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe GM1 Gangliosidosis Market

21.1. Eastern Europe GM1 Gangliosidosis Market Overview

21.2. Eastern Europe GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia GM1 Gangliosidosis Market

22.1. Russia GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America GM1 Gangliosidosis Market

23.1. North America GM1 Gangliosidosis Market Overview

23.2. North America GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA GM1 Gangliosidosis Market

24.1. USA GM1 Gangliosidosis Market Overview

24.2. USA GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada GM1 Gangliosidosis Market

25.1. Canada GM1 Gangliosidosis Market Overview

25.2. Canada GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America GM1 Gangliosidosis Market

26.1. South America GM1 Gangliosidosis Market Overview

26.2. South America GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil GM1 Gangliosidosis Market

27.1. Brazil GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East GM1 Gangliosidosis Market

28.1. Middle East GM1 Gangliosidosis Market Overview

28.2. Middle East GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa GM1 Gangliosidosis Market

29.1. Africa GM1 Gangliosidosis Market Overview

29.2. Africa GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. GM1 Gangliosidosis Market Competitive Landscape And Company Profiles

30.1. GM1 Gangliosidosis Market Competitive Landscape

30.2. GM1 Gangliosidosis Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Sarepta Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

31. GM1 Gangliosidosis Market Other Major And Innovative Companies

31.1. CRISPR Therapeutics AG

31.2. REGENXBIO Inc.

31.3. Passage Bio Inc.

31.4. Orchard Therapeutics plc

31.5. AVROBIO Inc.

31.6. uniQure N.V.

31.7. GEMMA Biotherapeutics Inc.

31.8. Lysogene S.A.

31.9. AZAFAROS B.V.

31.10. BioStrategies LC

31.11. Sio Gene Therapies Inc.

31.12. Gain Therapeutics Inc.

31.13. Dorphan S.A.

31.14. bluebird bio Inc.

31.15. Axovant Gene Therapies Ltd.

32. Global GM1 Gangliosidosis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The GM1 Gangliosidosis Market

34. Recent Developments In The GM1 Gangliosidosis Market

35. GM1 Gangliosidosis Market High Potential Countries, Segments and Strategies

35.1 GM1 Gangliosidosis Market In 2029 - Countries Offering Most New Opportunities

35.2 GM1 Gangliosidosis Market In 2029 - Segments Offering Most New Opportunities

35.3 GM1 Gangliosidosis Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global GM1 Gangliosidosis Market, Sub-Segmentation Of Type 1 GM1 Gangliosidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global GM1 Gangliosidosis Market, Sub-Segmentation Of Type 2 GM1 Gangliosidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global GM1 Gangliosidosis Market, Sub-Segmentation Of Type 3 GM1 Gangliosidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global GM1 Gangliosidosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global GM1 Gangliosidosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Asia-Pacific, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Asia-Pacific, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Asia-Pacific, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: China, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: China, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: China, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: India, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: India, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: India, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: Japan, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: Japan, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Japan, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Australia, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Australia, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Australia, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Indonesia, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Indonesia, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Indonesia, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: South Korea, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: South Korea, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: South Korea, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: Western Europe, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: Western Europe, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: Western Europe, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: UK, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: UK, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: UK, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: Germany, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: Germany, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: Germany, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: France, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: France, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: France, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: Italy, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: Italy, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: Italy, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Spain, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Spain, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Spain, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Eastern Europe, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Eastern Europe, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Eastern Europe, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Russia, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Russia, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Russia, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: North America, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: North America, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: North America, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: USA, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: USA, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: USA, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: Canada, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: Canada, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: Canada, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: South America, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: South America, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: South America, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: Brazil, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: Brazil, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: Brazil, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Middle East, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Middle East, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Middle East, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Africa, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Africa, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Africa, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Pfizer Inc. Financial Performance

Table 78: Sanofi S.A. Financial Performance

Table 79: Novartis AG Financial Performance

Table 80: Takeda Pharmaceutical Company Limited Financial Performance

Table 81: Sarepta Therapeutics Inc. Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global GM1 Gangliosidosis Market, Sub-Segmentation Of Type 1 GM1 Gangliosidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global GM1 Gangliosidosis Market, Sub-Segmentation Of Type 2 GM1 Gangliosidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global GM1 Gangliosidosis Market, Sub-Segmentation Of Type 3 GM1 Gangliosidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global GM1 Gangliosidosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global GM1 Gangliosidosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Asia-Pacific, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Asia-Pacific, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Asia-Pacific, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: China, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: China, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: China, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: India, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: India, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: India, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: Japan, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: Japan, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Japan, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Australia, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Australia, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Australia, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Indonesia, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Indonesia, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Indonesia, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: South Korea, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: South Korea, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: South Korea, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: Western Europe, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: Western Europe, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: Western Europe, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: UK, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: UK, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: UK, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: Germany, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: Germany, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: Germany, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: France, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: France, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: France, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: Italy, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: Italy, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: Italy, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Spain, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Spain, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Spain, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Eastern Europe, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Eastern Europe, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Eastern Europe, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Russia, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Russia, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Russia, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: North America, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: North America, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: North America, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: USA, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: USA, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: USA, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: Canada, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: Canada, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: Canada, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: South America, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: South America, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: South America, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: Brazil, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: Brazil, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: Brazil, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Middle East, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Middle East, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Middle East, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Africa, GM1 Gangliosidosis Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Africa, GM1 Gangliosidosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Africa, GM1 Gangliosidosis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Pfizer Inc. Financial Performance

Figure 78: Sanofi S.A. Financial Performance

Figure 79: Novartis AG Financial Performance

Figure 80: Takeda Pharmaceutical Company Limited Financial Performance

Figure 81: Sarepta Therapeutics Inc. Financial Performance

Intestinal Fistula Treatment Market Overview 2025: Competitive Shifts, Forecast Models, and Emerging Opportunities

Next-Gen Invasive Aspergillosis Therapeutics : Market Forecast, Transformation, and Long-Term Trajectories

Iron Deficiency Anemia Growth Trajectory: Key Forecasts and Strategic Insights

Lewy Body Dementia Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

A 2025 strategic report on market size, competitive landscape and expansion strategies in the medications for heart failure market.

Explore strategic insights and forecasts in the global virtual nutrition coach app market, offering competitive benchmarking and market growth trends.

Paraganglioma Global Market Report 2025 – By Type (Sympathetic Paragangliomas, Parasympathetic Paragangliomas, Caroid Paragangliomas, Cervical Paragangliomas, Jugular Paragangliomas, Secretory Paragangliomas, Temporal Pa...

Glycol Global Market Report 2025 – By Type (Ethylene Glycol, Propylene Glycol, Other Types), By Application (Antifreeze and Coolants, Polyester Fiber Production, PET Bottles and Packaging, Solvents and Humectants, Dehydr...

Glycomics or Glycobiology Global Market Report 2025 – By Product( Enzymes, Kits, Reagents and Chemicals, Instruments, Carbohydrates ), By Application( Drug Discovery and Development, Disease Diagnostics, Other Applicatio...

Glioma Treatment Global Market Report 2025 – By Type (Low-Grade, High-Grade), By Disease (Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Other Diseases), By Route Of Administration (Oral, ...

Bionematicides Global Market Report 2025 – By Type (Microbials, Biochemical), By Form (Dry Bionematicides, Liquid Bionematicides), By Crop (Cotton, Corn, Soybean, Fruits And Vegetables, Other Crops), By Application (Foli...

Anaplastic Astrocytoma Global Market Report 2025 – By Disease Type (Grade I, Grade II, Grade III, Grade IV), By Treatment Type (Surgery, Chemotherapy, Radiation), By Treatment Phase (Pre-Registration Phase, Clinical Tria...

Frequently Asked Questions

What is the definition of the GM1 Gangliosidosis market?

GM1 gangliosidosis is a rare, inherited neurodegenerative disorder caused by a deficiency of the β-galactosidase (GLB1) enzyme, leading to toxic accumulation of GM1 gangliosides in the brain and other tissues. It results in progressive neurological decline, developmental delays, muscle weakness, and organ enlargement. For further insights on this market, request a sample here

How will the GM1 Gangliosidosis market drivers and restraints affect the market dynamics? What forces will shape the GM1 Gangliosidosis industry going forward?

The market major growth driver - Rising Adoption Of Gene Therapy Fuels Growth In Rare Disease Treatments. For further insights on this market, request a sample here

What is the forecast market size or the forecast market value of the GM1 Gangliosidosis market?

The gm1 gangliosidosis market size has grown rapidly in recent years. It will grow from $0.51 billion in 2024 to $0.57 billion in 2025 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to increase in number of patients suffering from gm1 gangliosidosis, growing area of focus in the gm1 gangliosidosis space, rising prevalence of rare disease awareness, rising popularity of patient-centric research, and increasing focus on early intervention. The gm1 gangliosidosis market size is expected to see rapid growth in the next few years. It will grow to " $0.87 billion in 2029 at a compound annual growth rate (CAGR) of 11.0%. The growth in the forecast period can be attributed to increasing gm1 gangliosidosis cases, rising lysosomal storage disorder, rising number of clinical trials, increasing focus on gene therapy and editing, increasing personalized and precision medicine, and rising adoption of genetic screening programs. Major trends in the forecast period include advancements in gene-editing technologies, integration of technology in healthcare, advancement in diagnostic techniques, advanced formulations, and advancements in genetic therapies. For further insights on this market, request a sample here

How is the GM1 Gangliosidosis market segmented?

The gm1 gangliosidosismarket covered in this report is segmented –
1) By Disease Type: Type 1 GM1 Gangliosidosis; Type 2 GMT Gangliosidosis; Type 3 GMT Gangliosidosis
2) By Treatment: Anticonvulsants; Bone Marrow Transplantation; Cord-Blood Hematopoietic Stem-Cell Transplantation; Enzyme Replacement; Gene Therapy
3) By End-User: Research Institutes; Hospitals; Other End-Users Subsegments:
1) By Type 1 GM1 Gangliosidosis: Classic Infantile Onset; Atypical Infantile Onset
2) By Type 2 GM1 Gangliosidosis: Classic Juvenile Onset; Atypical Juvenile Onset
3) By Type 3 GM1 Gangliosidosis: Classic Adult Onset; Atypical Adult Onset For further insights on this market, request a sample here

Which region has the largest share of the GM1 Gangliosidosis market? What are the other regions covered in the report?

North America was the largest region in the GM1 gangliosidosis market in 2024. The regions covered in the GM1 gangliosidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Who are the major players in the GM1 Gangliosidosis market?

What are the key trends in the GM1 Gangliosidosis market?

Major trends in this market include Strategic Partnership To Advance Gene Therapies For Rare Diseases. For further insights on this market, request a sample here.